Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06072066 · ClinicalTrials.gov registry record · NA

Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

A NA study of Rosacea and Systemic Inflammation, sponsored by Integrative Skin Science and Research.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06072066 is a NA study of Rosacea and Systemic Inflammation that is actively recruiting participants, run by Integrative Skin Science and Research. The registered enrollment target is 24 participants, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06072066, a NA study of Rosacea and Systemic Inflammation, is actively recruiting participants, sponsored by Integrative Skin Science and Research.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.

Interventions

  • DIETARY_SUPPLEMENT Skin Barrier Oral Supplement

Study Locations (1)

California

  • Integrative Skin and Research - Sacramento

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-11-22
Est. Completion 2024-12-31
Phase NA

What the Registry Record Tells You About NCT06072066

The ClinicalTrials.gov registry entry for NCT06072066 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (90% lower). The listed sponsor is Integrative Skin Science and Research, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Skin Barrier Oral Supplement is the first listed.

NCT06072066 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06072066 about?

NCT06072066 is a clinical study titled "Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea". The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.

What is the current status of trial NCT06072066?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-11-22. Estimated completion is 2024-12-31.

What conditions does trial NCT06072066 study?

This clinical trial studies the following conditions: Rosacea, Systemic Inflammation.

What interventions are being tested in trial NCT06072066?

The interventions under investigation include: Skin Barrier Oral Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06072066?

This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06072066 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rosacea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.